Meaningful Presentations at the Annual Meeting of the American Association for Cancer Research (AACR) NEKTAR THERAPEUTICS …

Pursuing its goal in treating hepatitis, Gilead Sciences (GILD) is at the finish line of clinical trials on …

Regeneron and Intellia to Discover and Develop CRISPR/Cas Therapeutics Moving forward is Regeneron Pharmaceuticals’ (REGN) strategy based on strong …

Another day, another badly needed treatment for a dangerous disease is on its way to be …

Pfizer (PF) terminated its acquisition agreement with Allergan Plc (AGN) The new set of rules released by …

Prohost Letter #394 Part 2 PART 2 - Part 1 of the Prohost letter issue #394 posted …

Prohost Letter #394 Part 1 Gilead - Some people sold Gilead’s (GILD) stock on Wednesday, March 23 …

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 …

It is an ingenuous decision made by investors who rushed to consider betrixaban Phase 3 APEX study a …

Published articles in peer review journals cited that pharmacologic inhibition of RORγt regulates Th17 signature gene expression …